A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used in the treatment of diabetes and obesity (namely Ozempic, Rybelsus and Wegovy). After reviewing all available ...

and Wegovy. The medications, owned by Novo Nordisk (NYSE:NVO), are widely used for the treatment of diabetes and obesity. Following a comprehensive review of all available data, including non-clinical ...

Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration ...

Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used, a number of unintended side-effects have become apparent—with the ...

Experts warn more research is needed on long-term safety THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more ...

LOS ANGELES — American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with ...

Wegovy Use is Rising Among U.S. Teens as the Obesity Crisis Worsens. According to Data Shared With Reuters, More Teens Are Increasingly Turning to the Weight-loss Drug. It Comes as Families and Their ...